首页 > 最新文献

Journal of Geriatric Psychiatry and Neurology最新文献

英文 中文
Attitudes Towards Dementia Among a Diverse Group of Refugees Resettled in the United States. 在美国定居的不同难民群体对痴呆症的态度。
IF 2.9 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-03-01 Epub Date: 2024-09-03 DOI: 10.1177/08919887241280891
Dahlia A Kaki, Lana Bridi, Purity Mwendwa, Maryam Aso, Rawnaq Behnam, Nissma Bencheikh, Behnan Albahsahli, Xara Khan, Raghad Aljenabi, Alissa Bernstein Sideman, Alison Moore, Tala Al-Rousan

Background: Forced migration results in exposure to trauma, interrupted access to healthcare, and loss of social support and may increase dementia risk. Literature on refugees' knowledge of dementia and its risk factors is scant. This study investigates refugee perspectives on dementia and their access to cognitive healthcare in the United States (US).

Methods: We conducted 6 focus groups and 30 individual in-depth interviews (total of 69 participants) with Arab, African, and Afghan refugees resettled in San Diego, California. Data was coded using inductive thematic analysis.

Results: Organized by the socioecological model of health, the following themes emerged: (1) mental trauma due to migration was linked to dementia (individual); (2) fear of dementia and burdening caregivers due to limited support systems (interpersonal); (3) reliance on virtual communities for dementia information and the stress of local community loss increasing dementia risk (community); (4) healthcare providers, both in the US and in refugee camps, didn't address cognitive health concerns (institutions); and (5) discriminatory immigration and healthcare policies as barriers to healthy aging (policy).

Discussion: Despite being a heterogeneous group, refugees share specific experiences, knowledge gaps, and barriers to healthy aging. Tailored interventions and policies are needed to address this population's cognitive health needs. This includes addressing their mental health and social support concerns as well as training clinicians to screen for/discuss dementia with aging refugee patients.

背景:强迫迁移会导致难民遭受创伤、医疗服务中断、失去社会支持,并可能增加患痴呆症的风险。有关难民对痴呆症及其风险因素的了解的文献很少。本研究调查了难民对痴呆症的看法以及他们在美国获得认知医疗服务的情况:我们对重新安置在加利福尼亚州圣地亚哥的阿拉伯、非洲和阿富汗难民进行了 6 次焦点小组讨论和 30 次个人深度访谈(共 69 人参加)。采用归纳式主题分析法对数据进行编码:按照健康的社会生态模式进行组织,得出了以下主题:(1)移民造成的精神创伤与痴呆症有关(个人);(2)对痴呆症的恐惧和有限的支持系统给照顾者带来的负担(人际);(3)依赖虚拟社区获取痴呆症信息和当地社区消失的压力增加了痴呆症风险(社区);(4)美国和难民营的医疗保健提供者没有解决认知健康问题(机构);(5)歧视性移民和医疗保健政策是健康老龄化的障碍(政策)。讨论:尽管难民是一个异质群体,但他们在健康老龄化方面有着共同的经历、知识差距和障碍。需要制定有针对性的干预措施和政策,以满足这一群体的认知健康需求。这包括解决他们的心理健康和社会支持问题,以及培训临床医生与老年难民患者一起筛查/讨论痴呆症。
{"title":"Attitudes Towards Dementia Among a Diverse Group of Refugees Resettled in the United States.","authors":"Dahlia A Kaki, Lana Bridi, Purity Mwendwa, Maryam Aso, Rawnaq Behnam, Nissma Bencheikh, Behnan Albahsahli, Xara Khan, Raghad Aljenabi, Alissa Bernstein Sideman, Alison Moore, Tala Al-Rousan","doi":"10.1177/08919887241280891","DOIUrl":"10.1177/08919887241280891","url":null,"abstract":"<p><strong>Background: </strong>Forced migration results in exposure to trauma, interrupted access to healthcare, and loss of social support and may increase dementia risk. Literature on refugees' knowledge of dementia and its risk factors is scant. This study investigates refugee perspectives on dementia and their access to cognitive healthcare in the United States (US).</p><p><strong>Methods: </strong>We conducted 6 focus groups and 30 individual in-depth interviews (total of 69 participants) with Arab, African, and Afghan refugees resettled in San Diego, California. Data was coded using inductive thematic analysis.</p><p><strong>Results: </strong>Organized by the socioecological model of health, the following themes emerged: (1) mental trauma due to migration was linked to dementia (individual); (2) fear of dementia and burdening caregivers due to limited support systems (interpersonal); (3) reliance on <i>virtual communities</i> for dementia information and the stress of <i>local community loss</i> increasing dementia risk (community); (4) healthcare providers, both in the US and in refugee camps, didn't address cognitive health concerns (institutions); and (5) discriminatory immigration and healthcare policies as barriers to healthy aging (policy).</p><p><strong>Discussion: </strong>Despite being a heterogeneous group, refugees share specific experiences, knowledge gaps, and barriers to healthy aging. Tailored interventions and policies are needed to address this population's cognitive health needs. This includes addressing their mental health and social support concerns as well as training clinicians to screen for/discuss dementia with aging refugee patients.</p>","PeriodicalId":16028,"journal":{"name":"Journal of Geriatric Psychiatry and Neurology","volume":" ","pages":"132-142"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11783969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pyridostigmine for the Management of Neurogenic Orthostatic Hypotension: A Systemic Review. 吡啶斯的明治疗神经源性正张力性低血压:系统回顾。
IF 2.9 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-03-01 Epub Date: 2024-07-23 DOI: 10.1177/08919887241266800
Amanda C Holder, Angela Dylewski, Jamie N Brown

Background: Pyridostigmine is hypothesized to improve neurogenic orthostatic hypotension (nOH) symptoms without causing or exacerbating supine hypertension. The objective of this review was to evaluate the safety and efficacy of pyridostigmine for management of nOH.

Methods: A literature search of PubMed, Embase, and CENTRAL was performed in December 2023 for prospective trials with a placebo or active comparator.

Results: Four randomized and two non-randomized studies were reviewed. Three studies utilizing a single dose, crossover design found significant differences of orthostatics using adjunctive pyridostigmine. Two studies assessing longer-term endpoints demonstrated conflicting efficacy of pyridostigmine with one trial finding significant improvement in orthostatics and symptoms after three months of therapy. Use of pyridostigmine did not lead to supine hypertension with most adverse effects being cholinergic.

Conclusion: Pyridostigmine may be considered as an adjunctive medication in individuals with nOH refractory to standard treatment options as it carries a favorable safety profile with low risk for supine hypertension.

背景:据推测,吡啶斯的明可改善神经源性正张力性低血压(nOH)症状,而不会引起或加重仰卧位高血压。本综述旨在评估吡啶斯的明治疗 nOH 的安全性和有效性:方法:2023 年 12 月,我们在 PubMed、Embase 和 CENTRAL 中检索了含有安慰剂或活性比较药的前瞻性试验文献:结果:共审查了四项随机研究和两项非随机研究。三项采用单剂量、交叉设计的研究发现,使用吡啶斯的明辅助治疗后,患者的正侧位差异显著。两项评估长期终点的研究显示,吡啶斯的明的疗效相互矛盾,其中一项试验发现,治疗三个月后,正位和症状均有明显改善。使用吡啶斯的明不会导致仰卧位高血压,大多数不良反应是胆碱能性的:结论:对于标准治疗方案难以奏效的 nOH 患者,可以考虑将吡啶斯的明作为一种辅助药物,因为它具有良好的安全性,而且发生仰卧位高血压的风险较低。
{"title":"Pyridostigmine for the Management of Neurogenic Orthostatic Hypotension: A Systemic Review.","authors":"Amanda C Holder, Angela Dylewski, Jamie N Brown","doi":"10.1177/08919887241266800","DOIUrl":"10.1177/08919887241266800","url":null,"abstract":"<p><strong>Background: </strong>Pyridostigmine is hypothesized to improve neurogenic orthostatic hypotension (nOH) symptoms without causing or exacerbating supine hypertension. The objective of this review was to evaluate the safety and efficacy of pyridostigmine for management of nOH.</p><p><strong>Methods: </strong>A literature search of PubMed, Embase, and CENTRAL was performed in December 2023 for prospective trials with a placebo or active comparator.</p><p><strong>Results: </strong>Four randomized and two non-randomized studies were reviewed. Three studies utilizing a single dose, crossover design found significant differences of orthostatics using adjunctive pyridostigmine. Two studies assessing longer-term endpoints demonstrated conflicting efficacy of pyridostigmine with one trial finding significant improvement in orthostatics and symptoms after three months of therapy. Use of pyridostigmine did not lead to supine hypertension with most adverse effects being cholinergic.</p><p><strong>Conclusion: </strong>Pyridostigmine may be considered as an adjunctive medication in individuals with nOH refractory to standard treatment options as it carries a favorable safety profile with low risk for supine hypertension.</p>","PeriodicalId":16028,"journal":{"name":"Journal of Geriatric Psychiatry and Neurology","volume":" ","pages":"85-93"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141751902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Associations of Sensory Impairment With 10-Year Risk of Dementia and Alzheimer's Disease: The Health and Retirement Study, 2010-2020. 感官障碍与痴呆症和阿尔茨海默病 10 年风险的关系:2010-2020 年健康与退休研究》。
IF 2.9 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-03-01 Epub Date: 2024-08-26 DOI: 10.1177/08919887241275042
Kun Li, Rahul Ghosal, Donglan Zhang, Yike Li, Matthew C Lohman, Monique J Brown, Anwar T Merchant, Chih-Hsiang Yang, Jean Neils-Strunjas, Daniela B Friedman, Jingkai Wei

Background: Studies have examined the association between dual sensory impairment and late-life cognitive outcomes in the U.S with inconsistent findings.

Objective: To examine the associations between sensory impairment and 10-year risk of dementia or Alzheimer's disease among U.S. adults aged ≥ 50.

Methods: A prospective cohort study based on the Health and Retirement Study from 2010 to 2020. Individuals aged ≥ 50 years without self-reported dementia and Alzheimer's disease in 2010 were included in the analysis. Self-reported visual and hearing impairments were measures in 2010. Main failure events included self-reported incident dementia and Alzheimer's disease over a 10-year follow-up period. Participants were categorized as having no visual or hearing impairment, visual impairment only, hearing impairment only, and dual sensory impairment. Fine-Gray competing risk regression model was applied to estimate the associations of sensory impairment with incident dementia and Alzheimer's disease, adjusted for demographic characteristics, health behaviors, and health conditions at baseline.

Results: Of 20,248 identified individuals, 14.6% had visual impairment only, 11.2% had hearing impairment only, and 9.1% had dual impairment at baseline. After adjusting for all covariates, dual sensory impairment was associated with higher risk of dementia (HR = 1.46, 95% CI: 1.23-1.73) and Alzheimer's disease (HR = 1.35, 95% CI: 1.03-1.76). Visual impairment only was also associated with incident dementia and Alzheimer's disease among individuals <65 years.

Conclusion: Older adults in the U.S. with visual and hearing impairments simultaneously had a particularly greater risk of dementia and Alzheimer's disease, indicating the needs of targeted screening for timely treatment and further prevention of dementia and Alzheimer's disease.

背景:美国有多项研究探讨了双重感官障碍与晚年认知结果之间的关系,但结果并不一致:在美国,有研究探讨了双重感官障碍与晚年认知结果之间的关系,但结果并不一致:目的:在年龄≥50 岁的美国成年人中,研究感官障碍与痴呆症或阿尔茨海默病 10 年风险之间的关联:方法:一项基于 2010 年至 2020 年健康与退休研究的前瞻性队列研究。分析对象包括 2010 年年龄≥ 50 岁但未自我报告患有痴呆症和阿尔茨海默病的人。2010年自我报告的视力和听力障碍为测量指标。主要失败事件包括随访 10 年期间自我报告的痴呆症和阿尔茨海默病。参与者被分为无视力或听力障碍、仅有视力障碍、仅有听力障碍和双重感官障碍。应用Fine-Gray竞争风险回归模型来估计感官障碍与痴呆症和阿尔茨海默病的关联,并对人口特征、健康行为和基线健康状况进行调整:在 20248 名已确认的个体中,14.6% 的人在基线时仅有视力损伤,11.2% 的人仅有听力损伤,9.1% 的人有双重损伤。在对所有协变量进行调整后,双重感官障碍与痴呆症(HR = 1.46,95% CI:1.23-1.73)和阿尔茨海默病(HR = 1.35,95% CI:1.03-1.76)的高风险相关。在结论中,仅视力损伤也与痴呆症和阿尔茨海默病的发病有关:在美国,同时患有视力和听力障碍的老年人患痴呆症和阿尔茨海默病的风险特别高,这表明需要进行有针对性的筛查,以便及时治疗和进一步预防痴呆症和阿尔茨海默病。
{"title":"The Associations of Sensory Impairment With 10-Year Risk of Dementia and Alzheimer's Disease: The Health and Retirement Study, 2010-2020.","authors":"Kun Li, Rahul Ghosal, Donglan Zhang, Yike Li, Matthew C Lohman, Monique J Brown, Anwar T Merchant, Chih-Hsiang Yang, Jean Neils-Strunjas, Daniela B Friedman, Jingkai Wei","doi":"10.1177/08919887241275042","DOIUrl":"10.1177/08919887241275042","url":null,"abstract":"<p><strong>Background: </strong>Studies have examined the association between dual sensory impairment and late-life cognitive outcomes in the U.S with inconsistent findings.</p><p><strong>Objective: </strong>To examine the associations between sensory impairment and 10-year risk of dementia or Alzheimer's disease among U.S. adults aged ≥ 50.</p><p><strong>Methods: </strong>A prospective cohort study based on the Health and Retirement Study from 2010 to 2020. Individuals aged ≥ 50 years without self-reported dementia and Alzheimer's disease in 2010 were included in the analysis. Self-reported visual and hearing impairments were measures in 2010. Main failure events included self-reported incident dementia and Alzheimer's disease over a 10-year follow-up period. Participants were categorized as having no visual or hearing impairment, visual impairment only, hearing impairment only, and dual sensory impairment. Fine-Gray competing risk regression model was applied to estimate the associations of sensory impairment with incident dementia and Alzheimer's disease, adjusted for demographic characteristics, health behaviors, and health conditions at baseline.</p><p><strong>Results: </strong>Of 20,248 identified individuals, 14.6% had visual impairment only, 11.2% had hearing impairment only, and 9.1% had dual impairment at baseline. After adjusting for all covariates, dual sensory impairment was associated with higher risk of dementia (HR = 1.46, 95% CI: 1.23-1.73) and Alzheimer's disease (HR = 1.35, 95% CI: 1.03-1.76). Visual impairment only was also associated with incident dementia and Alzheimer's disease among individuals <65 years.</p><p><strong>Conclusion: </strong>Older adults in the U.S. with visual and hearing impairments simultaneously had a particularly greater risk of dementia and Alzheimer's disease, indicating the needs of targeted screening for timely treatment and further prevention of dementia and Alzheimer's disease.</p>","PeriodicalId":16028,"journal":{"name":"Journal of Geriatric Psychiatry and Neurology","volume":" ","pages":"94-105"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11841694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Socioenvironmental Factors are Associated With Dopamine Transporter Availability in Healthy Individuals but not in Parkinson's Disease. 社会环境因素与健康人多巴胺转运体的可用性有关,但与帕金森病无关。
IF 2.5 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-03-01 Epub Date: 2024-09-07 DOI: 10.1177/08919887241281062
Salih Cayir, Melike Tezel, David Matuskey

Objective: Social factors can influence the brain's dopaminergic function. This study investigated the relationship between socioenvironmental factors and dopamine transporter (DaT) availability in healthy individuals (n = 74) and those with Parkinson's disease (PD) (n = 240).

Methods: All single photon emission computed tomography (SPECT) DaT data and clinical data used in this study were obtained from the Parkinson's Progression Markers Initiative (PPMI) dataset. Socioenvironmental data was obtained from Social Explorer analyses of the American Community Survey (2014-2018) using the residential ZIP codes of the subjects available in the PPMI dataset.

Results: Participants resided in 302 ZIP code tabulation areas across 38 U.S. states. In healthy individuals, DaT signals were significant and negatively correlated in the caudate with median household income (r = -0.27, P = 0.02) and educational level of the living area (r = -0.23, P = 0.04), but not significant in the putamen (r = -0.21, P = 0.08; r = -0.11, P = 0.37 respectively). Also, there was a significant positive correlation between DaT signals in caudate and poverty rates (r = 0.29, P = 0.01), but not in the putamen (r = 0.16, P = 0.19) in healthy subjects. No significant associations were observed in the PD group for any variables.

Conclusion: The study findings suggest that socioenvironmental factors, such as median household income, education level, and poverty rate, are significantly associated with DaT availability in the caudate of healthy individuals but not in those with PD. This indicates that PD might disrupt the connection between the social environment and dopaminergic function. These results underscore the importance of considering socioenvironmental variables when studying dopaminergic function in the human brain.

目的社会因素会影响大脑的多巴胺能功能。本研究调查了健康人(n = 74)和帕金森病(PD)患者(n = 240)的社会环境因素与多巴胺转运体(DaT)可用性之间的关系:本研究使用的所有单光子发射计算机断层扫描(SPECT)DaT数据和临床数据均来自帕金森病进展标志物倡议(PPMI)数据集。社会环境数据来自 Social Explorer 对美国社区调查(2014-2018 年)的分析,使用的是 PPMI 数据集中受试者的居住地邮政编码:参与者居住在美国 38 个州的 302 个邮政编码表区。在健康人中,尾状体的DaT信号与家庭收入中位数(r = -0.27,P = 0.02)和居住地区的教育水平(r = -0.23,P = 0.04)呈显著负相关,但在普鲁士门不显著(分别为r = -0.21,P = 0.08;r = -0.11,P = 0.37)。此外,在健康受试者中,尾状核的 DaT 信号与贫困率之间存在明显的正相关(r = 0.29,P = 0.01),但在正视图中却不明显(r = 0.16,P = 0.19)。在帕金森病组中,没有观察到任何变量存在明显关联:研究结果表明,社会环境因素(如家庭收入中位数、教育水平和贫困率)与健康人尾状核的DaT可用性显著相关,但与帕金森病患者无关。这表明,帕金森病可能会破坏社会环境与多巴胺能功能之间的联系。这些结果强调了在研究人脑多巴胺能功能时考虑社会环境变量的重要性。
{"title":"Socioenvironmental Factors are Associated With Dopamine Transporter Availability in Healthy Individuals but not in Parkinson's Disease.","authors":"Salih Cayir, Melike Tezel, David Matuskey","doi":"10.1177/08919887241281062","DOIUrl":"10.1177/08919887241281062","url":null,"abstract":"<p><strong>Objective: </strong>Social factors can influence the brain's dopaminergic function. This study investigated the relationship between socioenvironmental factors and dopamine transporter (DaT) availability in healthy individuals (n = 74) and those with Parkinson's disease (PD) (n = 240).</p><p><strong>Methods: </strong>All single photon emission computed tomography (SPECT) DaT data and clinical data used in this study were obtained from the Parkinson's Progression Markers Initiative (PPMI) dataset. Socioenvironmental data was obtained from Social Explorer analyses of the American Community Survey (2014-2018) using the residential ZIP codes of the subjects available in the PPMI dataset.</p><p><strong>Results: </strong>Participants resided in 302 ZIP code tabulation areas across 38 U.S. states. In healthy individuals<b>,</b> DaT signals were significant and negatively correlated in the caudate with median household income (r = -0.27, <i>P</i> = 0.02) and educational level of the living area (r = -0.23, <i>P</i> = 0.04), but not significant in the putamen (r = -0.21, <i>P</i> = 0.08; r = -0.11, <i>P</i> = 0.37 respectively). Also, there was a significant positive correlation between DaT signals in caudate and poverty rates (r = 0.29, <i>P</i> = 0.01), but not in the putamen (r = 0.16, <i>P</i> = 0.19) in healthy subjects. No significant associations were observed in the PD group for any variables.</p><p><strong>Conclusion: </strong>The study findings suggest that socioenvironmental factors, such as median household income, education level, and poverty rate, are significantly associated with DaT availability in the caudate of healthy individuals but not in those with PD. This indicates that PD might disrupt the connection between the social environment and dopaminergic function. These results underscore the importance of considering socioenvironmental variables when studying dopaminergic function in the human brain.</p>","PeriodicalId":16028,"journal":{"name":"Journal of Geriatric Psychiatry and Neurology","volume":" ","pages":"143-149"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12473387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modifiable and Non-Modifiable Risk Factors for Dementia Among Non-Hispanic White and Black Populations Aged 50-64 in the United States, 2006-2016. 2006-2016 年美国 50-64 岁非西班牙裔白人和黑人中痴呆症的可改变和不可改变风险因素。
IF 2.9 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-03-01 Epub Date: 2024-07-22 DOI: 10.1177/08919887241267315
Jingkai Wei, Matthew C Lohman, Monique J Brown, James W Hardin, Chih-Hsiang Yang, Anwar T Merchant, Daniela B Friedman

Background and objectives: Non-Hispanic Black populations (NHB) have a significantly higher prevalence of dementia than non-Hispanic Whites in the U.S., and the underlying risk factors may play a role in this racial disparity. We aimed to calculate risk scores for dementia among non-Hispanic White (NHW) and non-Hispanic Black populations aged 50-64 years over a period of 10 years, and to estimate potential differences of scores between NHW and NHB.

Research design and methods: The Health and Retirement Study from 2006 to 2016 was used to calculate the Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) risk score, a validated score for predicting dementia risk. Weighted average CAIDE score, as well as CAIDE score for modifiable factors hypertension, obese, hypercholesterolemia, physical inactivity), and non-modifiable factors (age, sex, education) were calculated for adults aged 50-64 years with normal cognition for 2006-2008, 2010-2012, 2014-2016. The associations of race with CAIDE score and elevated CAIDE score were examined.

Results: A total of 10,871 participants were included in the analysis. The CAIDE score showed declining trends for NHB from 2006 to 2016, while NHB consistently had a higher total CAIDE score and CAIDE score for modifiable factors from 2006 to 2016, but not for non-modifiable factors.

Discussion and implications: NHB had a higher level of dementia risk factors than NHW among adults aged 50-64 years in the U.S. from 2006 to 2016, and the difference is attributable to modifiable risk factors, which holds promise for risk reduction of dementia.

背景和目标:在美国,非西班牙裔黑人(NHB)的痴呆症发病率明显高于非西班牙裔白人,而潜在的风险因素可能是造成这种种族差异的原因之一。我们的目的是计算 50-64 岁非西班牙裔白人(NHW)和非西班牙裔黑人在 10 年内患痴呆症的风险分数,并估计 NHW 和 NHB 之间分数的潜在差异:利用 2006 年至 2016 年的 "健康与退休研究"(Health and Retirement Study)来计算心血管风险因素、老龄化和痴呆症发病率(CAIDE)风险评分,这是预测痴呆症风险的有效评分。计算了2006-2008年、2010-2012年、2014-2016年认知正常的50-64岁成年人的加权平均CAIDE得分,以及可改变因素(高血压、肥胖、高胆固醇血症、缺乏运动)和不可改变因素(年龄、性别、教育程度)的CAIDE得分。研究还考察了种族与 CAIDE 得分和 CAIDE 得分升高之间的关系:共有 10871 名参与者参与了分析。从 2006 年到 2016 年,NHB 的 CAIDE 分数呈下降趋势,而从 2006 年到 2016 年,NHB 的 CAIDE 总分和可改变因素的 CAIDE 分数一直较高,但不可改变因素的 CAIDE 分数却不高:从2006年到2016年,在美国50-64岁的成年人中,NHB的痴呆症风险因素水平高于NHW,这种差异可归因于可改变的风险因素,这为降低痴呆症风险带来了希望。
{"title":"Modifiable and Non-Modifiable Risk Factors for Dementia Among Non-Hispanic White and Black Populations Aged 50-64 in the United States, 2006-2016.","authors":"Jingkai Wei, Matthew C Lohman, Monique J Brown, James W Hardin, Chih-Hsiang Yang, Anwar T Merchant, Daniela B Friedman","doi":"10.1177/08919887241267315","DOIUrl":"10.1177/08919887241267315","url":null,"abstract":"<p><strong>Background and objectives: </strong>Non-Hispanic Black populations (NHB) have a significantly higher prevalence of dementia than non-Hispanic Whites in the U.S., and the underlying risk factors may play a role in this racial disparity. We aimed to calculate risk scores for dementia among non-Hispanic White (NHW) and non-Hispanic Black populations aged 50-64 years over a period of 10 years, and to estimate potential differences of scores between NHW and NHB.</p><p><strong>Research design and methods: </strong>The Health and Retirement Study from 2006 to 2016 was used to calculate the Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) risk score, a validated score for predicting dementia risk. Weighted average CAIDE score, as well as CAIDE score for modifiable factors hypertension, obese, hypercholesterolemia, physical inactivity), and non-modifiable factors (age, sex, education) were calculated for adults aged 50-64 years with normal cognition for 2006-2008, 2010-2012, 2014-2016. The associations of race with CAIDE score and elevated CAIDE score were examined.</p><p><strong>Results: </strong>A total of 10,871 participants were included in the analysis. The CAIDE score showed declining trends for NHB from 2006 to 2016, while NHB consistently had a higher total CAIDE score and CAIDE score for modifiable factors from 2006 to 2016, but not for non-modifiable factors.</p><p><strong>Discussion and implications: </strong>NHB had a higher level of dementia risk factors than NHW among adults aged 50-64 years in the U.S. from 2006 to 2016, and the difference is attributable to modifiable risk factors, which holds promise for risk reduction of dementia.</p>","PeriodicalId":16028,"journal":{"name":"Journal of Geriatric Psychiatry and Neurology","volume":" ","pages":"106-114"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11783974/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141734284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implementing Arts on Prescription at Home for People Living With Dementia: A Hybrid-Effectiveness Feasibility Study. 在家中为痴呆症患者实施处方艺术:混合效果可行性研究。
IF 2.9 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-03-01 Epub Date: 2024-07-23 DOI: 10.1177/08919887241267335
Claire Mc O'Connor, Roslyn G Poulos, Michelle Heldon, Costanza Preti, Elizabeth Beattie, Christopher J Poulos

Arts on prescription at home (AoP@Home) is a participatory art-based approach involving a professional artist engaging a person with dementia (and their family carer) in art-making in their own home. This study evaluated the implementation of AoP@Home within a real-world community aged care context. A hybrid effectiveness-implementation design was used to simultaneously test both the AoP@Home intervention and the implementation process. AoP@Home program outcomes included person with dementia and family carer (dyad) health and wellbeing, and personal goal attainment. Implementation outcomes were evaluated according to feasibility, fidelity, acceptability, uptake, and costs via routinely collected data, artist notes, and interviews with program managers, artists, and participant dyads. Four dyads completed an AoP@Home program during the study period. All participants with dementia reported improvements in their overall health and wellbeing, and wellbeing scores improved for all carers from baseline to post-program. Implementation was feasible using existing government funding mechanisms, and programs were acceptable to all stakeholders. It is possible to deliver participatory arts programs for community-dwelling people with dementia and their family, in their home, using sustainable and available funding models. Programs such as AoP@Home should be made more accessible alongside broader allied health and care services.

家庭处方艺术(AoP@Home)是一种以艺术为基础的参与式方法,由专业艺术家在痴呆症患者(及其家庭照顾者)的家中让他们参与艺术创作。本研究评估了 "AoP@Home "在实际社区老年护理环境中的实施情况。研究采用了效果-实施混合设计,以同时测试 "AoP@Home "干预措施和实施过程。AoP@Home "计划的成果包括痴呆症患者和家庭照护者(双亲)的健康和福祉,以及个人目标的实现情况。通过日常收集的数据、艺术家笔记以及对项目经理、艺术家和参与者双方的访谈,对实施结果的可行性、忠实性、可接受性、吸收率和成本进行了评估。在研究期间,有四组参与者完成了 "AoP@Home "项目。所有痴呆症参与者都表示他们的整体健康和幸福感得到了改善,所有照护者的幸福感评分从基线到计划后都有所提高。利用现有的政府资助机制实施该计划是可行的,而且所有利益相关者都能接受该计划。利用可持续的可用资金模式,在社区居住的痴呆症患者及其家人家中开展参与式艺术项目是可行的。像 "AoP@Home "这样的项目应该与更广泛的联合医疗和护理服务一起,让更多人能够享受到。
{"title":"Implementing Arts on Prescription at Home for People Living With Dementia: A Hybrid-Effectiveness Feasibility Study.","authors":"Claire Mc O'Connor, Roslyn G Poulos, Michelle Heldon, Costanza Preti, Elizabeth Beattie, Christopher J Poulos","doi":"10.1177/08919887241267335","DOIUrl":"10.1177/08919887241267335","url":null,"abstract":"<p><p>Arts on prescription at home (AoP@Home) is a participatory art-based approach involving a professional artist engaging a person with dementia (and their family carer) in art-making in their own home. This study evaluated the implementation of AoP@Home within a real-world community aged care context. A hybrid effectiveness-implementation design was used to simultaneously test both the AoP@Home intervention and the implementation process. AoP@Home program outcomes included person with dementia and family carer (dyad) health and wellbeing, and personal goal attainment. Implementation outcomes were evaluated according to feasibility, fidelity, acceptability, uptake, and costs via routinely collected data, artist notes, and interviews with program managers, artists, and participant dyads. Four dyads completed an AoP@Home program during the study period. All participants with dementia reported improvements in their overall health and wellbeing, and wellbeing scores improved for all carers from baseline to post-program. Implementation was feasible using existing government funding mechanisms, and programs were acceptable to all stakeholders. It is possible to deliver participatory arts programs for community-dwelling people with dementia and their family, in their home, using sustainable and available funding models. Programs such as AoP@Home should be made more accessible alongside broader allied health and care services.</p>","PeriodicalId":16028,"journal":{"name":"Journal of Geriatric Psychiatry and Neurology","volume":" ","pages":"115-131"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11783976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141751901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vitamin D Deficiency in the Acute Phase of Stroke May Predict Post-stroke Depression: A Systematic Review and Meta-Analysis. 中风急性期维生素 D 缺乏可预测中风后抑郁:系统回顾与元分析》。
IF 2.9 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-03-01 Epub Date: 2024-08-23 DOI: 10.1177/08919887241275044
Yongjun Tan, Xiaojun Jing, Jiani Wang, Li Zhou, Yilin Wang, Hua Zhang, Qin Yang

Objective: To conduct the association between vitamin D levels in the acute phase of stroke and post-stroke depression (PSD) in stroke patients.

Methods: Five international databases (PubMed, Web of Science, Embase, Ovid MEDLINE(R), Cochrane Library) and one Chinese database (Wanfang Data) were searched for observational studies in any language reporting on PSD and vitamin D levels tested in the acute phase of stroke in stroke patients from inception to May 2024. Data extraction and study quality assessment were conducted by two authors independently. Qualitative and quantitative analyses of data were performed. The meta-analysis was registered in the PROSPERO database (CRD42023398581).

Results: We included 7 studies containing 3537 participants in the systematic review and meta-analysis. All studies that met the inclusion and exclusion criteria were conducted in China. Vitamin D levels in the acute phase of stroke were lower in PSD patients compared with non-PSD patients (weighted mean difference = -14.97 nmol/L; 95% confidence interval = -19.54, -10.40). Stroke patients with vitamin D deficiency (<50 nmol/L) had an increased risk of PSD compared with stroke patients with vitamin D sufficiency (≥75 nmol/L) (odds ratio = 3.59; 95% confidence interval = 2.05, 6.27). However, the association between vitamin D insufficiency (50-75 nmol/L) and PSD were not statistically significant (odds ratio = 4.15; 95% confidence interval = 0.87, 19.78).

Conclusion: Vitamin D deficiency in the acute phase of stroke may be a risk factor for PSD.

目的:探讨中风急性期维生素 D 水平与中风后抑郁(PSD)之间的关系:研究脑卒中急性期维生素 D 水平与脑卒中患者卒中后抑郁(PSD)之间的关系:方法:检索了五个国际数据库(PubMed、Web of Science、Embase、Ovid MEDLINE(R)、Cochrane Library)和一个中文数据库(万方数据),以任何语言检索了自开始至 2024 年 5 月期间有关卒中患者卒中急性期 PSD 和维生素 D 水平检测的观察性研究。数据提取和研究质量评估由两位作者独立完成。对数据进行定性和定量分析。荟萃分析结果已在 PROSPERO 数据库(CRD42023398581)中登记:我们在系统综述和荟萃分析中纳入了 7 项研究,共有 3537 名参与者。所有符合纳入和排除标准的研究均在中国进行。与非 PSD 患者相比,PSD 患者在卒中急性期的维生素 D 水平较低(加权平均差 = -14.97 nmol/L;95% 置信区间 = -19.54, -10.40)。缺乏维生素 D 的中风患者(结论:中风急性期维生素 D 缺乏可能是 PSD 的风险因素。
{"title":"Vitamin D Deficiency in the Acute Phase of Stroke May Predict Post-stroke Depression: A Systematic Review and Meta-Analysis.","authors":"Yongjun Tan, Xiaojun Jing, Jiani Wang, Li Zhou, Yilin Wang, Hua Zhang, Qin Yang","doi":"10.1177/08919887241275044","DOIUrl":"10.1177/08919887241275044","url":null,"abstract":"<p><strong>Objective: </strong>To conduct the association between vitamin D levels in the acute phase of stroke and post-stroke depression (PSD) in stroke patients.</p><p><strong>Methods: </strong>Five international databases (PubMed, Web of Science, Embase, Ovid MEDLINE(R), Cochrane Library) and one Chinese database (Wanfang Data) were searched for observational studies in any language reporting on PSD and vitamin D levels tested in the acute phase of stroke in stroke patients from inception to May 2024. Data extraction and study quality assessment were conducted by two authors independently. Qualitative and quantitative analyses of data were performed. The meta-analysis was registered in the PROSPERO database (CRD42023398581).</p><p><strong>Results: </strong>We included 7 studies containing 3537 participants in the systematic review and meta-analysis. All studies that met the inclusion and exclusion criteria were conducted in China. Vitamin D levels in the acute phase of stroke were lower in PSD patients compared with non-PSD patients (weighted mean difference = -14.97 nmol/L; 95% confidence interval = -19.54, -10.40). Stroke patients with vitamin D deficiency (<50 nmol/L) had an increased risk of PSD compared with stroke patients with vitamin D sufficiency (≥75 nmol/L) (odds ratio = 3.59; 95% confidence interval = 2.05, 6.27). However, the association between vitamin D insufficiency (50-75 nmol/L) and PSD were not statistically significant (odds ratio = 4.15; 95% confidence interval = 0.87, 19.78).</p><p><strong>Conclusion: </strong>Vitamin D deficiency in the acute phase of stroke may be a risk factor for PSD.</p>","PeriodicalId":16028,"journal":{"name":"Journal of Geriatric Psychiatry and Neurology","volume":" ","pages":"75-84"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142046755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neuropsychiatric Comorbidities and Psychotropic Medication Use in Medicare Beneficiaries With Dementia by Sex and Race. 按性别和种族分列的痴呆症医疗保险受益人的神经精神并发症和精神药物使用情况。
IF 2.9 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-01-01 Epub Date: 2024-05-20 DOI: 10.1177/08919887241254470
Kim G Johnson, Cassie Ford, Amy G Clark, Melissa A Greiner, Jay B Lusk, Cody Perry, Richard O'Brien, Emily C O'Brien

Background: Neuropsychiatric symptoms affect the majority of dementia patients. Past studies report high rates of potentially inappropriate prescribing of psychotropic medications in this population. We investigate differences in neuropsychiatric diagnoses and psychotropic medication prescribing in a local US cohort by sex and race.

Methods: We utilize Medicare claims and prescription fill records in a cohort of 100% Medicare North and South Carolina beneficiaries ages 50 and above for the year 2017 with a dementia diagnosis. We identify dementia and quantify diagnosis of anxiety, depression and psychosis using validated coding algorithms. We search Medicare claims for antianxiety, antidepressant and antipsychotic medications to determine prescriptions filled.

Results: Anxiety and depression were diagnosed at higher rates in White patients; psychosis at higher rates in Black patients. (P < .001) Females were diagnosed with anxiety, depression and psychosis at higher rates than males (P < .001) and filled more antianxiety and antidepressant medications than males. (P < .001) Black and Other race patients filled more antipsychotic medications for anxiety, depression and psychosis than White patients. (P < .001) Antidepressants were prescribed at higher rates than antianxiety or antipsychotic medications across all patients and diagnoses. Of patients with no neuropsychiatric diagnosis, 11.4% were prescribed an antianxiety medication, 22.8% prescribed an antidepressant and 7.6% prescribed an antipsychotic.

Conclusions: The high fill rate of antianxiety (benzodiazepine) medications in dementia patients, especially females is a concern. Patients are prescribed psychotropic medications at high rates. This practice may represent potentially inappropriate prescribing. Patient/caregiver education with innovative community outreach and care delivery models may help decrease medication use.

背景:神经精神症状影响着大多数痴呆症患者。过去的研究报告显示,在这一人群中,精神药物处方可能不当的比例很高。我们调查了美国当地队列中神经精神科诊断和精神药物处方在性别和种族上的差异:我们利用医疗保险报销单和处方填写记录,对 2017 年年龄在 50 岁及以上、诊断为痴呆症的 100%医疗保险北卡罗来纳州和南卡罗来纳州受益人进行队列研究。我们使用经过验证的编码算法识别痴呆症并量化焦虑症、抑郁症和精神病的诊断。我们搜索医疗保险报销单中的抗焦虑、抗抑郁和抗精神病药物,以确定处方:结果:白人患者中焦虑症和抑郁症的诊断率较高;黑人患者中精神病的诊断率较高(P < .001)。(P<0.001)女性被诊断为焦虑症、抑郁症和精神病的比例高于男性(P<0.001),所服用的抗焦虑和抗抑郁药物也多于男性(P<0.001)。(P<0.001)黑人和其他种族患者服用抗精神病药物治疗焦虑、抑郁和精神病的比例高于白人患者。(在所有患者和诊断中,抗抑郁药物的处方率均高于抗焦虑或抗精神病药物(P < .001)。在没有神经精神疾病诊断的患者中,11.4% 的患者处方了抗焦虑药,22.8% 的患者处方了抗抑郁药,7.6% 的患者处方了抗精神病药:老年痴呆症患者,尤其是女性患者,抗焦虑(苯二氮卓)药物的高填充率令人担忧。给患者开精神药物的比例很高。这种做法可能是不恰当的处方。通过创新的社区宣传和护理服务模式对患者/护理人员进行教育,可能有助于减少药物的使用。
{"title":"Neuropsychiatric Comorbidities and Psychotropic Medication Use in Medicare Beneficiaries With Dementia by Sex and Race.","authors":"Kim G Johnson, Cassie Ford, Amy G Clark, Melissa A Greiner, Jay B Lusk, Cody Perry, Richard O'Brien, Emily C O'Brien","doi":"10.1177/08919887241254470","DOIUrl":"10.1177/08919887241254470","url":null,"abstract":"<p><strong>Background: </strong>Neuropsychiatric symptoms affect the majority of dementia patients. Past studies report high rates of potentially inappropriate prescribing of psychotropic medications in this population. We investigate differences in neuropsychiatric diagnoses and psychotropic medication prescribing in a local US cohort by sex and race.</p><p><strong>Methods: </strong>We utilize Medicare claims and prescription fill records in a cohort of 100% Medicare North and South Carolina beneficiaries ages 50 and above for the year 2017 with a dementia diagnosis. We identify dementia and quantify diagnosis of anxiety, depression and psychosis using validated coding algorithms. We search Medicare claims for antianxiety, antidepressant and antipsychotic medications to determine prescriptions filled.</p><p><strong>Results: </strong>Anxiety and depression were diagnosed at higher rates in White patients; psychosis at higher rates in Black patients. (<i>P</i> < .001) Females were diagnosed with anxiety, depression and psychosis at higher rates than males (<i>P</i> < .001) and filled more antianxiety and antidepressant medications than males. (<i>P</i> < .001) Black and Other race patients filled more antipsychotic medications for anxiety, depression and psychosis than White patients. (<i>P</i> < .001) Antidepressants were prescribed at higher rates than antianxiety or antipsychotic medications across all patients and diagnoses. Of patients with no neuropsychiatric diagnosis, 11.4% were prescribed an antianxiety medication, 22.8% prescribed an antidepressant and 7.6% prescribed an antipsychotic.</p><p><strong>Conclusions: </strong>The high fill rate of antianxiety (benzodiazepine) medications in dementia patients, especially females is a concern. Patients are prescribed psychotropic medications at high rates. This practice may represent potentially inappropriate prescribing. Patient/caregiver education with innovative community outreach and care delivery models may help decrease medication use.</p>","PeriodicalId":16028,"journal":{"name":"Journal of Geriatric Psychiatry and Neurology","volume":" ","pages":"44-52"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141071247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Greater Apathy Associated With Selective Serotonin Reuptake Inhibitor Use in Parkinson's Disease. 帕金森病患者使用选择性羟色胺再摄取抑制剂会导致更严重的冷漠。
IF 2.5 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-01-01 Epub Date: 2024-05-23 DOI: 10.1177/08919887241254471
Rachel N Schade, Connor B Etheridge, Lauren E Kenney, Adrianna M Ratajska, Katie Rodriguez, Francesca V Lopez, Joshua Gertler, Alyssa Ray, Lauren Santos, Christopher Hess, Dawn Bowers

Objective: Apathy, a motivational disorder, is common in Parkinson's disease (PD) and often misdiagnosed as depression. Use of selective serotonin reuptake inhibitors (SSRIs) has been associated with increased apathy in adolescents and adults with depression. Based on observations that serotonin may downregulate dopaminergic systems, we examined the relationship between apathy and SSRI use in individuals with PD.

Methods: Medications, mood/motivation scales, and clinical data were collected from a convenience sample of 400 individuals with PD. Depression and apathy were measured using the Beck Depression Inventory-II (BDI-Il) and the Apathy Scale (AS). Antidepressant medications were grouped by mechanism type.

Results: Of the 400 PD patients, 26% were on SSRIs. On standard mood/motivation scales, 38% of the sample exceeded clinical cut-offs for apathy and 28% for depression. Results of hierarchical regression analyses revealed that SSRIs were the only antidepressant that were significantly associated with higher apathy scores (β = .1, P = .02). Less education (β = -.1, P = .01) worse cognition (β = -.1, P = .01), and greater depressive symptoms (β = .5, P < .001) were also significant predictors of apathy.

Conclusion: These findings suggest that use of SSRIs, but not other antidepressants, is associated with greater apathy in PD. Given the interactive relationship between serotonin and dopamine, the current findings highlight the importance of considering apathy when determining which antidepressants to prescribe to individuals with PD. Similarly, switching a SSRI for an alternative antidepressant in individuals with PD who are apathetic may be a potential treatment for apathy that needs further study.

目的:冷漠是帕金森病(PD)患者常见的一种动力障碍,常被误诊为抑郁症。使用选择性血清素再摄取抑制剂(SSRIs)与青少年和成人抑郁症患者的冷漠增加有关。据观察,血清素可能会下调多巴胺能系统,因此我们研究了患有帕金森病的患者的冷漠与使用SSRI之间的关系:方法:我们收集了 400 名帕金森病患者的药物、情绪/动机量表和临床数据。使用贝克抑郁量表-II(BDI-Il)和冷漠量表(AS)测量抑郁和冷漠。抗抑郁药物按机制类型分组:结果:在400名帕金森氏症患者中,26%服用了SSRIs。在标准情绪/动机量表中,38%的样本超过了冷漠的临床临界值,28%超过了抑郁的临床临界值。分层回归分析结果显示,SSRI 是唯一一种与较高的冷漠评分显著相关的抗抑郁药物(β = .1,P = .02)。教育程度较低(β = -.1,P = .01)、认知能力较差(β = -.1,P = .01)和抑郁症状较严重(β = .5,P < .001)也是冷漠的重要预测因素:这些研究结果表明,使用 SSRIs(而非其他抗抑郁药)与帕金森病患者更多的冷漠有关。鉴于血清素与多巴胺之间的互动关系,目前的研究结果突出表明,在决定为帕金森病患者开具哪种抗抑郁药时,必须考虑到淡漠问题。同样,对于情感淡漠的帕金森病患者,将SSRI换成其他抗抑郁药可能是一种潜在的治疗情感淡漠的方法,需要进一步研究。
{"title":"Greater Apathy Associated With Selective Serotonin Reuptake Inhibitor Use in Parkinson's Disease.","authors":"Rachel N Schade, Connor B Etheridge, Lauren E Kenney, Adrianna M Ratajska, Katie Rodriguez, Francesca V Lopez, Joshua Gertler, Alyssa Ray, Lauren Santos, Christopher Hess, Dawn Bowers","doi":"10.1177/08919887241254471","DOIUrl":"10.1177/08919887241254471","url":null,"abstract":"<p><strong>Objective: </strong>Apathy, a motivational disorder, is common in Parkinson's disease (PD) and often misdiagnosed as depression. Use of selective serotonin reuptake inhibitors (SSRIs) has been associated with increased apathy in adolescents and adults with depression. Based on observations that serotonin may downregulate dopaminergic systems, we examined the relationship between apathy and SSRI use in individuals with PD.</p><p><strong>Methods: </strong>Medications, mood/motivation scales, and clinical data were collected from a convenience sample of 400 individuals with PD. Depression and apathy were measured using the Beck Depression Inventory-II (BDI-Il) and the Apathy Scale (AS). Antidepressant medications were grouped by mechanism type.</p><p><strong>Results: </strong>Of the 400 PD patients, 26% were on SSRIs. On standard mood/motivation scales, 38% of the sample exceeded clinical cut-offs for apathy and 28% for depression. Results of hierarchical regression analyses revealed that SSRIs were the only antidepressant that were significantly associated with higher apathy scores (β = .1, <i>P</i> = .02). Less education (β = -.1, <i>P</i> = .01) worse cognition (β = -.1, <i>P</i> = .01), and greater depressive symptoms (β = .5, <i>P</i> < .001) were also significant predictors of apathy.</p><p><strong>Conclusion: </strong>These findings suggest that use of SSRIs, but not other antidepressants, is associated with greater apathy in PD. Given the interactive relationship between serotonin and dopamine, the current findings highlight the importance of considering apathy when determining which antidepressants to prescribe to individuals with PD. Similarly, switching a SSRI for an alternative antidepressant in individuals with PD who are apathetic may be a potential treatment for apathy that needs further study.</p>","PeriodicalId":16028,"journal":{"name":"Journal of Geriatric Psychiatry and Neurology","volume":" ","pages":"13-22"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12626153/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141081784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Comparison of Test-Retest Reliability and Practice Effects of Short Portable Mental State Questionnaire and Montreal Cognitive Assessment in Patients with Stroke. 脑卒中患者的便携式精神状态短问卷与蒙特利尔认知评估的测试-重测可靠性和实践效果比较。
IF 4.6 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-01-01 Epub Date: 2024-07-24 DOI: 10.1177/08919887241266793
Ta-Cheng Chen, Ya-Chen Lee, Yi-Ching Wang, Ton-Lin Hsieh, Mei-Hsiang Chen

Objective: To compare the test-retest reliabilities and minimal detectable change (MDC) of the Short Portable Mental State Questionnaire (SPMSQ) and the Montreal Cognitive Assessment (MoCA) in patients with stroke.

Methods: 63 patients were recruited from 1 medical center. The SPMSQ and MoCA were administered twice, 2 weeks apart.

Results: Both measures showed high intraclass correlation coefficients (SPMSQ: 0.87; MoCA: 0.89) and acceptable MDC%s (SPMSQ: 14.8%; MoCA: 19.6%). A small correlation (r = 0.30) was found between the absolute difference and average in each pair of assessments in the SPMSQ, which was close to the criterion of heteroscedasticity. A small practice effect was observed in the MoCA (Cohen's d = 0.30).

Conclusion: The SPMSQ demonstrated smaller random measurement error and an absence of practice effect. When comparing the psychometric properties of the SPMSQ and MoCA as outcome measures for assessing cognitive function in patients with stroke, the SPMSQ appears to be a more suitable choice than the MoCA.

目的比较脑卒中患者的便携式精神状态短问卷(SPMSQ)和蒙特利尔认知评估(MoCA)的测试再测可靠性和最小可检测变化(MDC)。方法:从 1 个医疗中心招募 63 名患者,两次进行 SPMSQ 和 MoCA 测试,每次间隔 2 周:结果:两种测量均显示出较高的类内相关系数(SPMSQ:0.87;MoCA:0.89)和可接受的 MDC%(SPMSQ:14.8%;MoCA:19.6%)。在 SPMSQ 中,每对评估的绝对差异和平均值之间存在微小的相关性(r = 0.30),接近异方差标准。在MoCA中观察到了较小的练习效应(Cohen's d = 0.30):结论:SPMSQ 的随机测量误差较小,不存在练习效应。在比较 SPMSQ 和 MoCA 作为评估脑卒中患者认知功能的结果测量工具的心理测量特性时,SPMSQ 似乎比 MoCA 更合适。
{"title":"A Comparison of Test-Retest Reliability and Practice Effects of Short Portable Mental State Questionnaire and Montreal Cognitive Assessment in Patients with Stroke.","authors":"Ta-Cheng Chen, Ya-Chen Lee, Yi-Ching Wang, Ton-Lin Hsieh, Mei-Hsiang Chen","doi":"10.1177/08919887241266793","DOIUrl":"10.1177/08919887241266793","url":null,"abstract":"<p><strong>Objective: </strong>To compare the test-retest reliabilities and minimal detectable change (MDC) of the Short Portable Mental State Questionnaire (SPMSQ) and the Montreal Cognitive Assessment (MoCA) in patients with stroke.</p><p><strong>Methods: </strong>63 patients were recruited from 1 medical center. The SPMSQ and MoCA were administered twice, 2 weeks apart.</p><p><strong>Results: </strong>Both measures showed high intraclass correlation coefficients (SPMSQ: 0.87; MoCA: 0.89) and acceptable MDC%s (SPMSQ: 14.8%; MoCA: 19.6%). A small correlation (<i>r</i> = 0.30) was found between the absolute difference and average in each pair of assessments in the SPMSQ, which was close to the criterion of heteroscedasticity. A small practice effect was observed in the MoCA (Cohen's <i>d</i> = 0.30).</p><p><strong>Conclusion: </strong>The SPMSQ demonstrated smaller random measurement error and an absence of practice effect. When comparing the psychometric properties of the SPMSQ and MoCA as outcome measures for assessing cognitive function in patients with stroke, the SPMSQ appears to be a more suitable choice than the MoCA.</p>","PeriodicalId":16028,"journal":{"name":"Journal of Geriatric Psychiatry and Neurology","volume":" ","pages":"53-61"},"PeriodicalIF":4.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141751900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Geriatric Psychiatry and Neurology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1